07:00 , Mar 26, 2012 |  BioCentury  |  Emerging Company Profile

ImmusanT: Having their cake

ImmusanT Inc. is developing what could be the first treatment for celiac disease that allows patients to eat a normal diet. The company's Nexvax2 vaccine seeks to reprogram CD4+ T cells to induce gluten tolerance. The...
08:00 , Feb 27, 2012 |  BC Week In Review  |  Clinical News

BioLineRx preclinical data

In gluten-sensitized mice, oral BL-7010 attenuated immune responses triggered by gluten and prevented gluten-induced pathological damage to the small intestine vs. untreated controls. Additionally, BL-7010 reduced digestion of wheat gluten and barley hordein in...